Anthracyclines: Clinical Trials

10 trials of Anthracyclines, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 2 terminated, 2 unknown, 1 active not recruiting. 10 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 310Completed 5, Terminated 2, Unknown 2, Active not recruiting 1
Phase 21Unknown 1

Follow Anthracyclines: new trials by email Literature Review of Anthracyclines trials Research Report on Anthracyclines

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML
Entospletinib, Placebo, Cytarabine - Nucleophosmin 1-mutated Acute Myeloid Leukemia
Phase 3TerminatedKronos Bio152021-11-242024-01-10
NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC
epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab, epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab - Breast Cancer, Triple Negative Breast Neoplasms
Phase 3Active not recruitingLund University Hospital3252019-12-202025-09-12
Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
nivolumab, paclitaxel (PTX), nivolumab placebo - Breast Cancer
Phase 3CompletedBristol-Myers Squibb5212019-11-182025-01-08
Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.
Midostaurin, Cytarabine, anthracycline ((daunorubicin or idarubicin): Induction Phase only - Acute Myeloid Leukemia
Phase 3CompletedNovartis Pharmaceuticals3012018-02-132024-02-29
Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy
paclitaxel/anthracycline - Primary Breast Cancer
Phase 3UnknownTao OUYANG4002011-03-042021-11-29
Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer
Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide, Docetaxel, cyclophosphamide - Breast Cancer
Phase 3TerminatedShanghai Jiao Tong University School of Medicine1022009-07-012016-11-22
Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents
Anthracyclines, liposomal daunorubicin, 2-CDA - Myeloid Leukemia
Phase 2 / Phase 3UnknownUniversity Hospital Muenster5502004-03-012012-05-23
A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care
Azacitidine, Physician Choice - Myelodysplastic Syndromes
Phase 3CompletedCelgene3582003-11-012019-10-29
Primary Chemotherapy With Adriamycin/Cyclophosphamide(AC) vs Taxotere/Xeloda(TX) for Stage II and III Breast Cancer
Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine - Breast Cancer
Phase 3CompletedNational Cancer Center, Korea2092002-06-012011-06-27
Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy
Anthracycline/dexamethasone-based induction chemotherapy, Dexamethasone for control of symptoms, Tumor-reduction chemotherapy and stem cell mobilization - Multiple Myeloma
Phase 3CompletedWiSP Wissenschaftlicher Service Pharma GmbH5492001-08-012014-11-11

Conditions studied

Breast Neoplasms (4)  ·  Leukemia, Myeloid, Acute (3)  ·  Leukemia (1)  ·  Leukemia, Myeloid (1)  ·  Multiple Myeloma (1)  ·  Myelodysplastic Syndromes (1)  ·  Neoplasms (1)  ·  Pathologic Complete Response (1)  ·  Triple Negative Breast Neoplasms (1)

Sponsors

Bristol-Myers Squibb (1)  ·  Celgene (1)  ·  Kronos Bio (1)  ·  Lund University Hospital (1)  ·  National Cancer Center, Korea (1)  ·  Novartis Pharmaceuticals (1)  ·  Shanghai Jiao Tong University School of Medicine (1)  ·  Tao OUYANG (1)  ·  University Hospital Muenster (1)  ·  WiSP Wissenschaftlicher Service Pharma GmbH (1)

Countries

Czechia (4)  ·  France (4)  ·  Germany (4)  ·  Italy (4)  ·  Spain (4)  ·  China (3)  ·  Hungary (3)  ·  Poland (3)  ·  Sweden (3)  ·  United States (3)  ·  Australia (2)  ·  Brazil (2)  ·  Bulgaria (2)  ·  Canada (2)  ·  Denmark (2)

Top investigators

CL Beach (1)  ·  Christian Straka, Prof. Dr. (1)  ·  Dirk Reinhardt, Prof. Dr. med. (1)  ·  Jungsil Ro, MD,PhD (1)  ·  Kunwei Shen (1)  ·  Niklas Loman, MD, PhD (1)  ·  Tao Ouyang, Doctor (1)  ·  Ursula Creutzig, Prof. Dr. med. (1)

Results publications

PMID 18083847, PMID 18182574, PMID 19230772, PMID 20026804, PMID 20136825, PMID 20394651, PMID 20451404, PMID 21480469, PMID 23585522, PMID 23704089, PMID 26814618, PMID 27269945, PMID 27662018, PMID 37581981, PMID 38913933, PMID 39838118, PMID 40803346

NIH funding

2016 (1)